Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Evaluation of Bevacizumab on 5-FU PK in Metastatic Colorectal Cancer
NCT00165568Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Dana-Farber Cancer Institute. Started Jul 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00165568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165568.